A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Subjects With Mild or Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2017
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Aragon Pharmaceuticals
- 21 Apr 2017 Status changed from recruiting to completed.
- 08 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.
- 25 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.